Journal of Clinical Investigation - Cardiology

JULY 15, 2024

The genetic deletion or pharmacological inhibition of the MC3R, or subthreshold doses of an MC4R agonist, improved the dose responsiveness to glucagon-like peptide 1 (GLP1) agonists, as assayed by inhibition of food intake and weight loss.

Pharmacology 98

Pharmacology Obesity 98

Circulation: Heart Failure

JANUARY 26, 2024

Circulation: Heart Failure, Ahead of Print.

Heart Failure 40

Heart Failure Pharmacology Obesity Outcomes 40

Frontiers in Cardiovascular Medicine

FEBRUARY 4, 2024

Notably, MAM exhibits various regulatory effects to maintain cellular balance in several cardiac diseases conditions, such as obesity, diabetes mellitus, and cardiotoxicity. Cardiac diseases caused by any reason can lead to changes in myocardial structure and function, significantly impacting human health.

Pharmacology 69

Pharmacology Obesity Heart Failure Diabetes 69

Journal of Cardiovascular Pharmacology

DECEMBER 11, 2023

The impact of severe obesity on weight-based heparin dosing is not well studied. Lower heparin dose (U/kg) was required in obese patients to achieve target ACT. In conclusion, there is significant variability in the therapeutic effect of heparin, with a lower weight-adjusted heparin dose required in obese patients.

Obesity 40

Obesity BMI Article 40

International Journal of Cardiovascular Sciences

MARCH 13, 2023

These factors include obesity, dyslipidemia, hypertension, and insulin resistance — also known as metabolic syndrome. Numerous pharmacological and non-pharmacological interventions have been developed to control and improve clinical outcomes, and all these aspects involve cardiometabolic diseases.

Pharmacology 52

Pharmacology Article Obesity Risk Factors 52

Journal of Clinical Investigation - Cardiology

DECEMBER 15, 2023

Conflicting studies in recent years report that genetic or pharmacological increases or decreases in ghrelin either increase or have no effect on islet size. Both germline and conditional ghrelin-knockout mice associated with increased islet size, which was further exacerbated by older age and diet-induced obesity.

Pharmacology 45

Pharmacology Diet Obesity Diabetes 45

HeartRhythm

SEPTEMBER 4, 2024

This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We highlight the misperception that pharmacologic heart rate lowering is beneficial, which has resulted in an overprescription of beta-blockers in HFpEF and AF.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Quality of Life 40

Journal of Cardiovascular Pharmacology

JUNE 24, 2024

Sodium/glucose cotransporter 2 (SGLT2) inhibitors are a novel class of anti-diabetic medications which have proved capable of providing breakthrough cardiovascular benefits in a variety of clinical scenarios, including patients with heart failure or obesity, irrespective of diabetic status.

Myocardial Infarction 40

Myocardial Infarction Heart Failure Pharmacology Diabetes 40

Frontiers in Cardiovascular Medicine

DECEMBER 18, 2024

Atrial fibrillation (AF), the most prevalent cardiac arrhythmia, is closely linked to metabolic dysfunctions, including obesity, diabetes, and dyslipidemia. These lead to pathological changes in myocardial metabolism and mitochondrial energy metabolism, thereby aggravating AF's incidence and severity.

Atrial Fibrillation 40

Atrial Fibrillation Exercise Pharmacology Obesity 40

Journal of the American Heart Association

FEBRUARY 26, 2025

BackgroundAbdominal aortic aneurysm (AAA) is a severe aortic disease for which no pharmacological interventions have yet been developed. Journal of the American Heart Association, Ahead of Print. Further investigations are needed to clarify the specific roles of these proteins in AAA pathology.

Aneurysm 40

Aneurysm Risk Factors Aortic Obesity 40

ADN Center of Excellence

SEPTEMBER 2, 2024

Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase. From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving.

AFIB 59

AFIB Atrial Fibrillation Innovation Heart Rhythm 59

ADN Center of Excellence

SEPTEMBER 2, 2024

Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase. From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving.

AFIB 52

AFIB Atrial Fibrillation Innovation Heart Rhythm 52

Cardiometabolic Health Congress

OCTOBER 25, 2024

Aronne, MD , discussed advances in obesity pharmacology, while Virend K. Day 2: Expanding the Horizons of Cardiometabolic Health Day 2 featured groundbreaking presentations from leading cardiometabolic health pioneers. Experts like Louis J. Florez, MD, PhD , explored the future of precision medicine in diabetes.

CME 64

CME Innovation Education Atherosclerosis 64

DAIC

FEBRUARY 29, 2024

24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

Cardiometabolic Health Congress

JULY 25, 2023

Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Dr. Paddy Barrett

APRIL 5, 2024

New obesity medications such as GLP-1 agonists have shown significant reductions in weight in those with a prior heart attack. JACC Volume 79, Issue 17 , 3 May 2022, Pages 1690-1700 9 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. This is a key part of the nutrition guidance provided during cardiac rehab.

Heart Disease 119

Heart Disease Coronary Artery Disease Heart Attack Heart attacks 119

Cardiometabolic Health Congress

MAY 10, 2024

Results revealed that women are twice as likely to exhibit myocardial ischemia in response to mental stress compared to traditional stressors like exercise or pharmacologic stress. Inflammation plays a pivotal role in both depression and obesity, while stress elevates cortisol levels, often initiating this cycle.

Coronary Artery Disease 59

Coronary Artery Disease Obesity Chest Pain Ischemia 59

DAIC

MAY 21, 2024

Hypertension, high cholesterol, and obesity are among the most common risk factors of cardiovascular disease and mortality — but getting these risk factors under control can be very challenging,” said Edo Paz, MD , the study’s lead author and SVP, Medical Affairs, Hello Heart. Of 102,475 participants, 49.1% were female.

Blood Pressure 52

Blood Pressure Cholesterol Risk Factors BMI 52

DAIC

JANUARY 23, 2024

1,12,13 While it is important to treat all known risk factors that contribute to ASCVD including high blood pressure, hyperlipidemia, diabetes, and obesity, physicians also need to recognize and treat systemic inflammation in CV disease. Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review.

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

Journal of Clinical Investigation - Cardiology

MARCH 17, 2025

This was functionally important, as inhibition of LIPA genetically or pharmacologically resulted in lower plasma FFAs under lipolytic conditions. Furthermore, adipocyte LIPA deficiency impaired thermogenesis and oxygen consumption and rendered mice susceptible to diet-induced obesity.

Pharmacology 95

Pharmacology Diet Obesity 95